Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Endologix, LLC

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Endologix, LLC

Regulatory records
7
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 7 FDA records to the applicant name Endologix, LLC. It includes 1 original PMA approval. 4 entries are PMA supplements. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jun 7, 2023 to Oct 16, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code QWM appears in 6 of the 7 linked filings. The collection spans 2 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P220021, with 6 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 3910 Brickway Blvd., Santa Rosa, CA, 95403. Recorded on P220021/S009, decision dated Oct 16, 2026.

Changes described in PMA records

P220021/S009: DETOUR System

The FDA record for P220021/S009, titled "DETOUR System" with the decision code OK30 and dated 2026-10-16, lists this action as a 30-Day Notice under the supplement reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The reported statement describes approval for changes to visual acceptance criteria for TORUS SGDS Latch and Pulley Subassembly components. The record does not explain what those criteria are, what the prior criteria specified, or how the subassembly is manufactured, so those details remain absent from the supplied fields.

The P220021 identifier alone establishes the parent PMA relationship; it does not show that the full DETOUR System was newly approved. The product code QWM, the superficial femoral artery stent graft category, and the applicant Endologix, LLC, appear in the supplied fields. The stated purpose concerns visual acceptance criteria, not proof of safety or clinical effectiveness, and none of the supplied fields report trial data or clinical outcomes.

FDA approval-order wording

approval for changes to visual acceptance criteria for TORUS SGDS Latch and Pulley Subassembly components

Oct 16, 2026 · 30-Day Notice

P120006/S045: Alto Abdominal Stent Graft System

FDA’s recorded scope: approval of changes to the supplier performing processing of the nitinol wire used in manufacturing of the Alto device.

Jun 3, 2026 · 135 Review Track For 30-Day Notice

P220021/S007: DETOUR System

FDA’s recorded scope: changes to the stent graft lot release testing and criteria

Jan 22, 2026 · 135 Review Track For 30-Day Notice

P220021/S008: DETOUR System

FDA’s recorded scope: implementation of new semi-automated crimping equipment and an in-process verification test during manufacturing of the TORUS SG

Dec 23, 2025 · 30-Day Notice

P220021/S006: DETOUR System

FDA’s recorded scope: a manufacturing site located at Endologix, LLC at 3910 Brickway Blvd., Santa Rosa, CA 95403 for manufacturing the TORUS Stent Graft System and associated manufacturing changes and for an alternate contract sterilizer for the TORUS Stent Graft System located at Steris Isomedix Services at 43425 Business Park Drive, Temecula, CA 92590

Oct 9, 2025 · Normal 180 Day Track No User Fee

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
DETOUR SystemP220021/S009
Endologix, LLCPMA supplementOct 16, 2026FDA
Endologix, LLCPMA supplementJun 3, 2026FDA
DETOUR SystemP220021/S007
Endologix, LLCPMA supplementJan 22, 2026FDA
DETOUR SystemP220021/S008
Endologix, LLCPMA supplementDec 23, 2025FDA
DETOUR SystemP220021/S006
Endologix, LLCPMA supplementOct 9, 2025FDA
DETOUR SystemP220021/S005
Endologix, LLCPMA supplementSep 18, 2025FDA
Endologix, LLCPMA approvalJun 7, 2023FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.